FIELD: pharmaceutics; chemistry.
SUBSTANCE: invention relates to the field of pharmaceutics and chemistry, namely to a pharmaceutical composition for the treatment of primary biliary cirrhosis in a subject, containing a complex of a nanoparticle, the core of which is related to a number of antigen-MHC class II (hereinafter – pMHCII) complexes. The core contains iron oxide, and its diameter is from 1 nm to 25 nm. Antigen is PDC-E2 or its fragment capable of inducing an immune response. The number of related pMHCII per the surface area of the nanoparticle is from 0.4 pMHC/100 nm2 to 12 pMHC/100 nm2. pMHCII are related to a maleimide-functionalized end of a polyethylene glycol (hereinafter – PEG) linker, the molecular weight of which is less than 5 kDa. A non-maleimide-functionalized end of polyethylene glycol (PEG) linker is related to the core surface. In this case, the complex differentiates an activated T-cell or a memory T-cell to a cell TR1 producing IL-10. The nanoparticle complex is present in the amount sufficient for the treatment of primary biliary cirrhosis in a subject.
EFFECT: treatment of primary biliary cirrhosis in a subject due to the capability of pMHC, on the nanoparticle core, of initiating the formation of TR1 cells suppressing an antigen-specific response, with regulated density of pMHC on the nanoparticle core.
9 cl, 22 dwg, 24 tbl, 3 ex
